Literature DB >> 27141072

Clear-cell carcinoma of the ovary.

K Fujiwara1, D Shintani2, T Nishikawa2.   

Abstract

Clear-cell carcinoma of the ovary (CCCO) is a distinct entity of epithelial ovarian cancer in terms of clinical, histopathological, or genetic features. The incidence of CCCO is different by ethnicity but the reason is not clear yet. Overall prognosis of CCCO is good because most CCCO is found in stage I. However, advanced disease is associated with a very poor prognosis and resistance to standard treatment. The same is true for recurrent disease. Therefore, genetic analysis of CCCO is important to find the right target(s) and better therapeutic approaches. Because of its rarity, international collaboration is necessary to conduct randomized clinical trials for CCCO.
© The Author 2016. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Year:  2016        PMID: 27141072     DOI: 10.1093/annonc/mdw086

Source DB:  PubMed          Journal:  Ann Oncol        ISSN: 0923-7534            Impact factor:   32.976


  23 in total

1.  Thrombotic events induce the worse prognosis in ovarian carcinomas and frequently develop in ovarian clear cell carcinoma.

Authors:  Kazuki Takasaki; Morikazu Miyamoto; Masashi Takano; Hiroaki Soyama; Tadashi Aoyama; Hiroko Matsuura; Hideki Iwahashi; Hiroki Ishibashi; Takahiro Sakamoto; Kenichi Furuya
Journal:  Int J Clin Oncol       Date:  2019-05-09       Impact factor: 3.402

2.  The worsening impact of programmed cell death ligand 1 in ovarian clear cell carcinomas.

Authors:  Hiroko Matsuura; Morikazu Miyamoto; Taira Hada; Hiroki Ishibashi; Hideki Iwahashi; Soichiro Kakimoto; Rie Suzuki; Tsubasa Ito; Jin Suminokura; Hitoshi Tsuda; Masashi Takano
Journal:  Arch Gynecol Obstet       Date:  2022-05-04       Impact factor: 2.344

3.  Hypoxia-induced Maspin Expression Affects the Prognosis of Ovarian Clear Cell Carcinoma.

Authors:  Eun Ji Lee; Soo Jin Park; Cheol Lee; Ga Won Yim; Jae Weon Kim; Hee Seung Kim
Journal:  In Vivo       Date:  2022 Jan-Feb       Impact factor: 2.155

4.  Genomic scar signatures associated with homologous recombination deficiency predict adverse clinical outcomes in patients with ovarian clear cell carcinoma.

Authors:  Angel Chao; Chyong-Huey Lai; Tzu-Hao Wang; Shih-Ming Jung; Yun-Shien Lee; Wei-Yang Chang; Lan-Yang Yang; Fei-Chun Ku; Huei-Jean Huang; An-Shine Chao; Chin-Jung Wang; Ting-Chang Chang; Ren-Chin Wu
Journal:  J Mol Med (Berl)       Date:  2018-05-03       Impact factor: 4.599

Review 5.  Targeting epigenetics using synthetic lethality in precision medicine.

Authors:  Ee Sin Chen
Journal:  Cell Mol Life Sci       Date:  2018-07-12       Impact factor: 9.261

6.  Inhibition of PI3K/AKT/mTOR and MAPK signaling pathways decreases progranulin expression in ovarian clear cell carcinoma (OCCC) cell line: a potential biomarker for therapy response to signaling pathway inhibitors.

Authors:  Carlos Eduardo Perez-Juarez; Fabian Arechavaleta-Velasco; Moises Zeferino-Toquero; Lourdes Alvarez-Arellano; Isaias Estrada-Moscoso; Laura Diaz-Cueto
Journal:  Med Oncol       Date:  2019-11-12       Impact factor: 3.064

7.  Tetraspanin 1 promotes endometriosis leading to ovarian clear cell carcinoma.

Authors:  Ha-Yeon Shin; Wookyeom Yang; Doo Byung Chay; Eun-Ju Lee; Joon-Yong Chung; Hyun-Soo Kim; Jae-Hoon Kim
Journal:  Mol Oncol       Date:  2021-01-07       Impact factor: 6.603

8.  Response to sunitinib (Sutent) in chemotherapy refractory clear cell ovarian cancer.

Authors:  C Alifrangis; A Thornton; C Fotopoulou; J Krell; H Gabra
Journal:  Gynecol Oncol Rep       Date:  2016-11-06

Review 9.  Genomic alterations in gynecological malignancies: histotype-associated driver mutations, molecular subtyping schemes, and tumorigenic mechanisms.

Authors:  Seiichi Mori; Osamu Gotoh; Kazuma Kiyotani; Siew Kee Low
Journal:  J Hum Genet       Date:  2021-06-07       Impact factor: 3.172

10.  Kinetics of HE4 and CA125 as prognosis biomarkers during neoadjuvant chemotherapy in advanced epithelial ovarian cancer.

Authors:  Jorge A Alegría-Baños; José C Jiménez-López; Arely Vergara-Castañeda; David F Cantú de León; Alejandro Mohar-Betancourt; Delia Pérez-Montiel; Gisela Sánchez-Domínguez; Mariana García-Villarejo; César Olivares-Pérez; Ángel Hernández-Constantino; Acitlalin González-Santiago; Miguel Clara-Altamirano; Liz Arela-Quispe; Diddier Prada-Ortega
Journal:  J Ovarian Res       Date:  2021-07-19       Impact factor: 4.234

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.